Form 4: AEON Biopharma's Chief Medical Officer, Chad Oh, Receives Stock Awards
SEC Form 4
Chad Oh, Chief Medical Officer of AEON Biopharma, was granted restricted stock units and stock options on August 31, 2024.
Summary
- Chad Oh, the Chief Medical Officer of AEON Biopharma, received an award of 192,117 shares of Class A Common Stock in the form of restricted stock units on August 31, 2024.
- These restricted stock units will vest in full on the second anniversary of the grant date, contingent upon Oh's continued service.
- Oh also received an award of 512,673 stock options on August 31, 2024, exercisable at a price of $0.83 per share.
- These options vest in equal monthly installments over 18 months following the grant date, also subject to continued service.
- The filing also corrects a previous error, reclassifying 100,428 restricted stock units granted on April 26, 2023, from derivative securities to common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, indicating confidence in the company's future, but doesn't contain any groundbreaking news.
Positives
- The grant of restricted stock units and stock options to the Chief Medical Officer aligns his interests with the long-term success of the company.
- The vesting schedules incentivize continued service and contribution to AEON Biopharma.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.
Industry Context
Stock grants and options are common forms of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align their interests with shareholder value.
Comparison to Industry Standards
- Stock option and RSU grants are standard practice in the biotech industry for executive compensation.
- Companies like Amgen, Biogen, and Gilead Sciences routinely use similar instruments to incentivize their leadership teams.
- The vesting schedules (2 years for RSUs, 18 months for options) are fairly typical, aligning with industry norms for retention and performance incentives.
Stakeholder Impact
- Shareholders may view the stock and option grants as a positive sign, indicating that the company is investing in its leadership.
- Employees may see this as a positive sign of the company's commitment to its executives.
Key Dates
| Date | Description |
|---|---|
| 04/26/2023 | Original grant date of 100,428 restricted stock units (RSUs) that were incorrectly reported as derivative securities. |
| 07/24/2023 | Previous reporting date where RSUs were incorrectly reported as derivative securities. |
| 08/31/2024 | Date of the grant of 192,117 restricted stock units and 512,673 stock options to Chad Oh. |
| 08/30/2034 | Expiration date of the stock options granted on August 31, 2024. |
| 09/04/2024 | Date of the Form 4 filing. |
Keywords
AEON Biopharma, Chad Oh, Chief Medical Officer, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.